Shopping Cart
- Remove All
Your shopping cart is currently empty
Xentuzumab
🥰Excellent
Catalog No. T76795Cas No. 1417158-65-6
Alias BI 836845
Xentuzumab (BI836845) is a recombinant monoclonal antibody to humanised IGF ligand that inhibits IGF1 and IGF2 growth-promoting signalling and inhibits AKT activation for the study of solid tumours.
Xentuzumab
🥰Excellent
Purity: 95%
Catalog No. T76795Alias BI 836845Cas No. 1417158-65-6
Xentuzumab (BI836845) is a recombinant monoclonal antibody to humanised IGF ligand that inhibits IGF1 and IGF2 growth-promoting signalling and inhibits AKT activation for the study of solid tumours.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $347 | In Stock | |
| 5 mg | $886 | In Stock | |
| 10 mg | $1,450 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "Xentuzumab"
2,3-Butanediol
T19094513-85-9
2,3-Butanediol, derived from the bioconversion of natural resources, holds significant potential for various industries, including chemical, cosmetics, agriculture, and pharmaceutical sectors.
- $40
Size
QTY
Artemisinin
Cited
Qinghaosu,Artemisinine, Qinghaosu, NSC 369397, Artemisinine
T039263968-64-9
Artemisinin (Qinghaosu) is a natural product, a sesquiterpene lactone, derived from Artemisia annua. Artemisinin has anti-malarial activity, as well as neuroprotective and anti-tumor activity.
- $30
Size
QTY
CitedEthyl gallate Cited
Phyllemblin, Nipagallin A, gallic acid ethyl ester
T3729831-61-8
Ethyl gallate (gallic acid ethyl ester) obviously decreases cell proliferation in MDA-MB-231 and MCF-7 cells in a dose- and time-dependent manner, exhibits cytotoxicity in a dose-dependent manner. Ethyl gallate can inhibit the abilities of invasion of breast cancer in vitro by inhibiting the mRNA levels of MMP-9/MMP-2, phosphorylation of Akt and protein expression of NF-κB and inhibits hydrogen peroxide signaling, may represent an alternative class of vasopressors for use in septic shock. Also, Ethyl gallate suppresses proliferation and invasion in human breast cancer cells by modulating the PI3K/Akt pathway, which may contribute to inhibiting their downstream targets such as NF-κB p-65, Bcl-2/Bax, and mRNA levels of MMP-2 and MMP-9 in breast cancer cells, could be used as potential antioxidants with safe therapeutic application in cancer chemotherapy.
- $42
Size
QTY
CitedHonokiol Cited
NSC 293100
T300135354-74-6
Honokiol (NSC-293100) is the active principle of magnolia extract. It inhibits the activation of Akt and enhances the phosphorylation of ERK1/ERK2.
- $50
Size
QTY
CitedOridonin Cited
Rubescensin A, Rubescenin, NSC-250682, Isodonol
T279028957-04-2
Oridonin (NSC-250682) is a diterpenoid isolated from Rabdosia rubescens with anti-tumor, anti-bacterial and anti-inflammatory effects. It acts as an inhibitor of AKT, with IC50s of 8.4 and 8.9 μM for AKT1 and AKT2.
- $45
Size
QTY
CitedIndirubin Derivative E804
T11654854171-35-0In house
Indirubin Derivative E804 is a potent insulin-like growth factor type 1 receptor (IGF1R) inhibitor with potential antitumor activity.
- $42
Size
QTY
Ceritinib Cited
LDK378
T17911032900-25-6
Ceritinib (LDK378) is an ALK tyrosine kinase inhibitor (IC50=200 pM) with selective, ATP-competitive, and oral activity. Ceritinib also inhibits IGF-1R, InsR, and STK22D (IC50=8/7/23 nM). Ceritinib has antitumor activity.
- $45
Size
QTY
CitedAKT Kinase Inhibitor
T10276842148-40-7In house
AKT Kinase Inhibitor is an Akt inhibitor with antitumor activity that selectively inhibits cell proliferation in a dose-dependent manner.
- $138
Size
QTY
Scutellarin Cited
Scutellarein-7-glucuronide, Breviscapinun, Breviscapine, Breviscapin
T278927740-01-8
Scutellarin (Scutellarein-7-glucuronide), an active flavone isolated from Scutellaria baicalensis, can inhibit RANKL-mediated MAPK and NF-κB signaling pathway in osteoclasts, and down-regulate the STAT3/Girdin/Akt signaling in HCC cells.
- $45
Size
QTY
CitedCapivasertib Cited
AZD5363
T19201143532-39-1
Capivasertib (AZD5363) is a broad-spectrum AKT inhibitor with inhibitory activity against Akt1, Akt2, and Akt3 (IC50=3/7/7 nM) with oral activity. Capivasertib has antitumor activity for the treatment of breast cancer.
- $34
Size
QTY
CitedMethyl-Hesperidin
T022811013-97-1
Methyl Hesperidin, a flavanone glycoside (flavonoid) (C28H34O15), is abundant in citrus fruits. Its aglycone form is called hesperetin.
- $50
Size
QTY
ALK-IN-1
Brigatinib-analog, AP26113-analog, AP26113
T30591197958-12-5
ALK-IN-1 (AP26113) is a potent ALK inhibitor with IC50 of 0.62 nM in a cell-free assay, demonstrated ability overcome Crizotinib resistance mediated by a L1196M mutation. Phase 2.
- $40
Size
QTY
Select Batch
Concentration:2.26 mg/mL
Purity:95%
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Chemical Properties
| Description | Xentuzumab (BI836845) is a recombinant monoclonal antibody to humanised IGF ligand that inhibits IGF1 and IGF2 growth-promoting signalling and inhibits AKT activation for the study of solid tumours. |
| In vitro | After 5 or 10 days of incubation, single-agent Xentuzumab(XENT)or ENZA reduced the viability of VCaP, DuCaP, and MDA PCa 2b cells in a dose-dependent manner. Combination therapy further decreased cell viability compared to monotherapy; likewise, treatment with XENT+ENZA resulted in a significant reduction in the expression of cell cycle genes, ubiquitin-conjugating enzyme E2 C (UBE2C), cyclin-dependent kinase 1 (CDK1), and cell division cycle protein 20 (CDC20) compared to single-agent treatment.[1]. |
| In vivo | Monotherapy with ENZA did not inhibit tumor growth. However, the addition of Xentuzumab(XENT)rendered the tumors sensitive to ENZA again, leading to a significant reduction in tumor volume[1]. |
| Alias | BI 836845 |
| Molecular Weight | 143.7 kDa |
| Cas No. | 1417158-65-6 |
Storage & Solubility Information
| Storage | store at low temperature | store at -80°C | Shipping with blue ice. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Xentuzumab | purchase Xentuzumab | Xentuzumab cost | order Xentuzumab | Xentuzumab chemical structure | Xentuzumab in vivo | Xentuzumab in vitro | Xentuzumab molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.